Double antiviral attack: could two flu drugs beat one for vulnerable patients?

NCT ID NCT04712539

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether combining two antiviral drugs, baloxavir and oseltamivir, works better than oseltamivir alone for severe flu in people with weakened immune systems (such as blood cancer patients or stem cell transplant recipients). The study will measure how quickly the virus clears and whether the combination reduces hospital stays or complications. 60 participants are being recruited at MD Anderson Cancer Center.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Baloxavir marboxil and oseltamivir

What this could lead to

If it works, this combination could offer a more effective treatment for severe flu in people with weakened immune systems, reducing hospital stays and complications.

What could go wrong

This is a small, early-phase trial (60 participants) in a very specific group (cancer or transplant patients). The combination may not work better than oseltamivir alone, and there is a risk of side effects or drug resistance.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INFLUENZA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm influenza

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • M D Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact